Intra-Cellular Therapies, Inc. is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to deliver innovative treatments for people living with complex psychiatric and neurologic diseases. WORK WITH US Patient needs are at the core of our efforts at Intra-Cellular Therapies and we are always looking for talented individuals who share our values to join our team. Please explore open positions by clicking the “Jobs” tab above.
View Top Employees from Intra-Cellular TherapiesWebsite | http://www.intracellulartherapies.com |
Ticker | ITCI |
Revenue | $245 million |
Funding | $1.1 billion |
Employees | 577 (568 on RocketReach) |
Founded | 2002 |
Address | 430 East 29th Street Suite 955, New York, New York 10016, US |
Phone | (646) 440-9333 |
Fax | (646) 440-9334 |
Technologies | |
Industry | Pharmaceutical Manufacturing, Pharmaceuticals, Biotechnology, Drug Discovery, Healthcare, Science and Engineering, Health Care, Medical Device |
Web Rank | 3 Million |
Keywords | Psychiatric Treatments, Innovative Treatments, Pharmaceutical Therapies |
Competitors | Acadia Pharmaceuticals Inc., Boston Life Sciences Inc, Reata Pharmaceuticals, Inc., Vanda Pharmaceuticals, Xenon Pharmaceuticals Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Intra-Cellular Therapies employee's phone or email?
The Intra-Cellular Therapies annual revenue was $245 million in 2024.
Suresh Durgam is the Chief Medical Officer of Intra-Cellular Therapies.
568 people are employed at Intra-Cellular Therapies.
Intra-Cellular Therapies is based in New York, New York.
The NAICS codes for Intra-Cellular Therapies are [54, 541, 32541, 3254, 325, 32].
The SIC codes for Intra-Cellular Therapies are [28, 283].